Flagship Pioneering unveils microbiome-focused company

Flagship Pioneering announced Kaleido Biosciences Inc. (Bedford, Mass.), a biopharmaceuticals company that uses its chemistry platform to discover and develop products that modulate the metabolic profile of the microbiome in order to treat and prevent severe diseases. Kaleido has been operating in stealth since it was founded by the life science venture firm in 2015.

On Monday, Geoffrey von Maltzahn, partner at Flagship Pioneering, said Kaleido has raised an undisclosed funding round. Kaleido also named Mike Bonney CEO and chairman. He was CEO of Cubist Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired...